Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 2Brain Neoplasms 2Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Glioblastoma 1ALK-positive NSCLC 1ALK-positive Advanced Tumors 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × ceritinib × Clear all
NCT02292550 2020-12-17

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Novartis

Phase 1 Completed
27 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡